Cardiogeni PLCAQUIS: CGNI

Cardiogeni: Delay in Publication of Accounts and Suspension

· Issued by Cardiogeni PLC

Summary by 6ix AI

Cardiogeni PLC, a UK biotechnology company developing heart regeneration medicines, said publication of its audited annual accounts for the year ended March 31, 2026 will be delayed beyond September 30, 2026. Trading in its shares is suspended from 7.30 a.m. on October 1, 2026 until the accounts are published.

Key details

  • The company says the delay is due to auditor resourcing constraints, which led to the appointment of a new auditor, HaysMac, later in the process than usual.
  • The suspension applies to trading in the shares on the Aquis Stock Exchange Growth Market.
  • The company says the audit is progressing well.

What’s still pending

  • The company expects to publish its audited annual accounts in the second half of October 2026.
  • The company will seek restoration of trading once the audited annual accounts are published.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/delay-in-publication-of-accounts-and-suspension-2

1 October 2026

Cardiogeni PLC

("Cardiogeni" or the "Company")

Annual report update and temporary suspension from trading

Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to develop and commercialise novel heart regeneration medicines, announces that the publication of its audited annual accounts for the year ended 31 March 2026 will be delayed beyond 30 September 2026. This is due to auditor resourcing constraints, which led to the appointment of a new auditor, HaysMac, later in the process than usual.

As a result, trading in the Company's shares on the Aquis Stock Exchange Growth Market will be suspended with effect from 7.30 a.m. today, pending publication of the audited annual accounts.

The audit is progressing well and the Company expects to publish its audited annual accounts in the second half of October 2026, at which point it will seek restoration of trading, and will provide further updates as appropriate.

Contacts

Cardiogeni PLC

Dr Darrin M Disley, Executive Chairman
Ajan Reginald, Executive Officer

Via First Sentinel

First Sentinel Corporate Finance Limited, Corporate Adviser

Brian Stockbridge
Gabrielle Cordeiro

+44 020 3855 5551

SP Angel Corporate Finance LLP, Corporate Broker

David Hignell
Vadim Alexandre

Devik Mehta

+44 20 3470 0470

Cardiogeni PLC on 6ix

Earlier from Cardiogeni

Later from Cardiogeni

All Cardiogeni news releases